Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 50 (2), 377-89

Pharmacological Treatment of Obesity

Affiliations
Review

Pharmacological Treatment of Obesity

Marcio C Mancini et al. Arq Bras Endocrinol Metabol.

Abstract

This review offers an overview of physiological agents, current therapeutics, as well as medications, which have been extensively used and those agents not currently available or non-classically considered anti-obesity drugs. As obesity - particularly that of central distribution - represents an important triggering factor for insulin resistance, its pharmacological treatment is relevant in the context of metabolic syndrome control. The authors present an extensive review on the criteria for anti-obesity management efficacy, on physiological mechanisms that regulate central and/or peripheral energy homeostasis (nutrients, monoamines, and peptides), on beta-phenethylamine pharmacological derivative agents (fenfluramine, dexfenfluramine, phentermine and sibutramine), tricyclic derivatives (mazindol), phenylpropanolamine derivatives (ephedrin, phenylpropanolamine), phenylpropanolamine oxytrifluorphenyl derivative (fluoxetine), a naftilamine derivative (sertraline) and a lipstatine derivative (orlistat). An analysis of all clinical trials - over ten-week long - is also presented for medications used in the management of obesity, as well as data about future medications, such as a the inverse cannabinoid agonist, rimonabant.

Similar articles

  • Treatment of Obesity: An Update on Anti-Obesity Medications
    A Halpern et al. Obes Rev 4 (1), 25-42. PMID 12608525. - Review
    The information presented in this article provides an overview of physiological agents, therapeutics in current use, and medications that have been extensively used in th …
  • [Pharmacological Therapy of Obesity]
    U Pagotto et al. G Ital Cardiol (Rome) 9 (4 Suppl 1), 83S-93S. PMID 18773755.
    Obesity is reaching epidemic proportions worldwide and it is correlated with various comorbidities, among which the most relevant are diabetes mellitus, arterial hyperten …
  • [Pharmacotherapy in the Treatment of Obesity]
    A Hamann. MMW Fortschr Med 148 (9), 36-8. PMID 16566392. - Review
    Currently, the substances orlistat and sibutramine are approved drugs for the pharmacotherapy of obesity. Used in combination with increased exercise and dietary measures …
  • Long-term Effects of Weight-Reducing Drugs in People With Hypertension
    A Siebenhofer et al. Cochrane Database Syst Rev 3, CD007654. PMID 26934640. - Review
    In people with elevated blood pressure, orlistat and sibutramine reduced body weight to a similar degree, while phentermine/topiramate reduced body weight to a greater ex …
  • [Drug Treatment of Obesity]
    OL Svendsen et al. Ugeskr Laeger 168 (2), 163-7. PMID 16403342. - Review
    Acceptable adverse effects and a clinical relevant weight loss of 3 to 5 kilograms have been found in long-term randomized clinical trials for sibutramine (Reductil) and …
See all similar articles

Cited by 3 PubMed Central articles

LinkOut - more resources

Feedback